The optimal protocol for mobilization of hematopoietic stem cells in patients with lymphoid malignancies has not been determined so far. We retrospectively analyzed the efficacy and safety of Ara-C at a dose of 1.6 g/m 2 compared with CY at a dose of 4.0 g/m 2 , both combined with filgrastim. Seventy and forty-five patients, respectively, were included, among whom 60% were defined as 'predicted poor mobilizers'. The use of Ara-C was associated with significantly higher peak number of circulating CD34
INTRODUCTION
Autologous hematopoietic SCT (autoHSCT) is a standard treatment of patients with multiple myeloma (MM) and selected patients with Hodgkin's (HL) or non-Hodgkin's lymphoma (NHL). Currently, 99% of the procedures are performed using peripheral blood as a source of stem cells. 1 The minimal number of CD34 þ cells required for neutrophil and platelet recovery after autoHSCT is 2 Â 10 6 /kg. However, some data indicate that higher levels are associated with less need for blood product transfusions and administration of antibiotics, as well as prolonged survival in both MM and lymphoma settings. [2] [3] [4] [5] [6] [7] Furthermore, patients planned for double autoHSCT, as used in MM, require relatively higher CD34 þ cell yields. Therefore, 5 Â 10 6 cells/kg is considered the optimal level. [8] [9] [10] Mobilization protocols may either be based on the use of cytokines alone, most frequently G-CSF, or cytokines in combination with chemotherapy. Chemomobilization was demonstrated to increase CD34 þ cell yield. 11 On the other hand, it may produce severe toxicity and the need for transfusions. 11 In patients with MM, CY at a wide dose range 1.5-7 g/m 2 is most commonly used for mobilization. 12 For patients with lymphomas, mobilization is often a part of salvage multiagent chemotherapy. Unfortunately, 5-40% of patients fail to mobilize sufficient number of CD34 þ cells. 6, [13] [14] [15] Several factors were identified to predict poor mobilization, including increasing patients' age, thrombocytopenia and long-term antecedent chemotherapy. [16] [17] [18] [19] [20] [21] [22] New mobilization strategies have been investigated including the use of plerixafor, CXCR4 inhibitor, in combination with G-CSF, with or without chemotherapy. This agent enabled effective CD34 þ cell harvest in 64. .6% of the 'proven' or 'predicted poor mobilizers'. 23, 24 However, the optimal, costeffective first-line regimen for procurement of autoHSCTs remains unknown.
Most patients are referred to our transplant center from other ones after completion of their first-or subsequent-line therapies and are frequently heavily pre-treated. Therefore, our mobilization strategy aiming to collect the optimal number of CD34 þ cells is oriented toward efficacy, and based on chemotherapy in combination with G-CSF. CY 4 g/m 2 þ G-CSF was initially used as a first-line attempt. In cases of mobilization failure, we introduced Ara-C at the dose of 2.4 g/m 2 þ G-CSF following Montillo et al., 25 who used this combination in a setting of 14 patients with CLL among whom eight had failed previous mobilization with G-CSF alone. We further decreased the dose of Ara-C to 1.6 g/m 2 to minimize hematologic toxicity. Both doses appeared highly effective allowing adequate CD34 þ cell harvest in 14 consecutive cases. 26 As a consequence, we decided to change our standard operating procedures and introduce intermediate-dose Ara-C þ G-CSF as the first-line mobilization for patients with lymphoid malignancies. In this study, we retrospectively analyzed the efficacy and toxicity of Ara-C þ G-CSF in comparison with CY þ G-CSF.
SUBJECTS AND METHODS Patients
We analyzed results of 70 consecutive patients with lymphoid malignancies treated with Ara-C þ G-CSF between July 2011 and March 2012, and 45 patients mobilized with CY þ G-CSF between April 2010 and June 2011 in Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland. Only patients with at least PR of their disease and proven chemosensitivity were accepted for autoHSCT in our center. The median age was 57 years (20-69 years) and did not differ between the treatment groups. As well, other clinical characteristics were comparable except for more frequent thrombocytopenia found among patients treated with CY than Ara-C (Table 1) . In respective groups, 18 (41%) and 28 (40%) patients were classified as 'predicted poor mobilizers', according to criteria recently proposed by Gruppo Italiano Trapianto di Midollo Osseo. 27 Mobilization regimens Ara-C was administered as a 2 h i.v. infusion at a dose of 0.4 g/m 2 twice daily on days 1 and 2 (total dose 1.6 g/m 2 ). CY was given at a dose of 2 g/m 2 on days 1 and 2 (total dose 4 g/m 2 ), with adequate hydration (3 L) and administration of mesna. G-CSF (filgrastim) (7-10 mg/kg) was started on day 5 and continued until last leukapheresis. Anti-emetic prophylaxis consisted of ondansetron 2 Â 8 mg per day. Patients were hospitalized either during the whole mobilization period or only during the chemotherapy administration and leukaphereses. The choice was dependent mainly on logistic aspects, for example, the distance from the patients' place of living to the hospital. No anti-infectious prophylaxis was routinely used. Platelet transfusions were indicated when the platelet level dropped below 20 Â 10 9 /L or below 50 Â 10 9 /L with concomitant need for introduction of the central venous catheter. Packed RBC transfusions were administered to maintain Hb level 48 g/dL. Toxicity of both procedures was assessed using Common Terminology Criteria for Adverse Events Version 4.0.
Leukaphereses
The number of circulating CD34
þ cells was first evaluated on the second day of neutrophil recovery 41 Â 10 9 /L in patients who experienced grade 3 or 4 neutropenia or, in remaining patients, on the first day with increase of neutrophil count. The analysis was done with the use of flow cytometry, as previously described. 27 Leukapheresis was started when the CD34 þ blood level was at least 10/mL. If the level was not achieved, G-CSF administration was continued and CD34 þ cell counted until CD34 þ level decreased compared to the preceding day. Leukaphereses were performed using Spectra-Optia Apheresis System (CaridianBCT Inc, Lakewood, CO, USA) according to the manufacturers' Table 1 . Patients characteristics 'Predicted poor mobilizers' were defined as the presence of one major criterion (previous extensive radiotherapy to marrow bearing tissue or full courses of previous therapy potentially affecting stem cell mobilization), or at least two minor criteria (advanced phase disease, refractory disease, BM involvement at mobilization, BM cellularity o30%, or age 465 years). 27 stem cell mobilization with Ara-C S Giebel et al protocols for mononuclear cell harvesting, processing two blood volumes. The target CD34 þ cell yield was 42 Â 10 6 /kg for patients with HL and NHL (planned for a single autoHSCT), whereas 45 Â 10 6 /kg for patients with MM (all planned for tandem autoHSCT).
Collected cells were cryopreserved using a controlled-rate freezer in 10% DMSO, and stored in liquid nitrogen. Additionally, in randomly selected 13 patients, 1 mL of the product was cryopreserved separately and further tested in a clonogenic assay, for the presence of burst-forming unit-erythroid (BFU-E), CFU-erythroid (CFU-E); CFU-granulocyte/macrophage (CFU-GM) and CFU-erythroid, granulocyte, macrophage, megakaryocyte (CFU-GEMM), as previously described. 28 
Statistical methods
The peak number of circulating CD34 þ cells, number of collected CD34 þ cells and the ratio of patients who collected sufficient CD34 þ cell yield for autoHSCT were primary study end points. The differences between Ara-C and CY groups were evaluated with the use of U Mann-Whitney test for quantitative variables and Fisher's exact test, two sided, for qualitative variables. Time to neutrophil and platelet recovery was estimated using the Kaplan-Meier method. The probabilities were compared using log-rank test. Differences with P values o0.05 were considered statistically significant. Statistical analysis was performed using Statistica software version 10 (StatSoft Inc., Tulsa, OK, USA).
RESULTS

Analysis of circulating CD34
þ cells
The peak number of circulating CD34 þ cells/mL was significantly higher after Ara-C þ G-CSF (median 120 (range, 0-523)) compared with CY þ G-CSF [33 (1-240), Po0.0001). As well, the proportion of patients who reached at least 10 CD34 þ cells/mL was higher for Ara-C than CY (97 versus 76%, P ¼ 0.0005). Significant differences in favor of Ara-C þ G-CSF were found in separate analysis of patients with MM or lymphomas ( Table 2 ). In addition, 93% of 'predicted poor mobilizers' reached at least 10 CD34
þ cells/mL after Ara-C þ G-CSF compared with 67% in the CY cohort (P ¼ 0.04).
Analysis of stem cell harvest Altogether 68 patients proceeded to leukaphereses in the Ara-C group, and 37 patients in the CY group (three patients despite CD34
þ cell blood level o10/mL, that is, 9/mL, 9/mL and 8/mL). Leukaphereses were started significantly later in patients receiving Ara-C þ G-CSF than CY þ G-CSF (day 14 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) versus day 12 (11) (12) (13) (14) (15) (16) (17) (18) (19) , Po0.0001). In the Ara-C group, 57 patients (84%) were started stem cell harvest between day 13 and 15, most frequently on day 14 (28 patients, 41%). s.d. equaled 1.1 day. In the CY group leukaphereses were started between day 12 and 14 in 32 (86%) patients and s.d. was 1.6. Number of collected CD34 þ cells was significantly higher for patients mobilized with Ara-C þ G-CSF (14.5 Â 10 6 /kg (2.2-54.6)) than after CY þ G-CSF (5.1 Â 10 6 /kg (0.9-14.3), Po0.0001). The difference remained significant when three patients with CD34
þ cell yield o10/mL were excluded from the analysis (Po0.0001). A single apheresis was sufficient to collect adequate numbers of CD34 þ cells in 91% patients in the Ara-C group compared with 24% in the CY group (Po0.0001). Similar differences were observed in subgroup of patients with MM and lymphomas, analyzed separately. As well, among 'predicted poor mobilizers' the CD34 þ cell yield was significantly higher after Ara-C þ G-CSF than after CY þ G-CSF (8.3 Â 10 6 /kg (2.2-52.1) versus 4.4 Â 10 6 /kg (0.9-13.9), P ¼ 0.01), which was achieved with a single apheresis in 85 and 20% of patients, respectively (P ¼ 0.0001).
The efficacy of mobilization and harvest Altogether 68 out of 70 patients (97%) treated with Ara-C þ G-CSF collected at least 2 Â 10 6 CD34 þ cells/kg, and 58 patients (83%) collected at least 5 Â 10 6 CD34 þ cells/kg (Table 3) . Among patients with high risk of mobilization failure, respective proportions were 95 and 72%. In particular, 95% patients with MM achieved sufficient CD34 þ yield for double autoHSCT and 97% of patients with lymphomas-for a planned single procedure. The efficacy of the mobilization and harvest procedure was significantly lower for CY þ G-CSF with 62% of patients yielding at The differences remained statistically significant after excluding patients with thrombocytopenia at mobilization (Po0.0001 for the peak level of circulating CD34 þ cells and P ¼ 0.004 for proportion of patients with peak level X10 CD34 þ cells/mL).
stem cell mobilization with Ara-C S Giebel et al least 2 Â 10 6 CD34 þ cells/kg (Po0.0001) and 49% yielding at least 5 Â 10 6 CD34 þ cells/kg (P ¼ 0.0002). The CD34 þ yield was adequate for transplantation in 67% of patients with MM (P ¼ 0.005, compared to Ara-C) and 48% patients with HL or NHL (Po0.0001). Finally, among 'predicted poor mobilizers' 2 Â 10 6 and 5 Â 10 6 CD34 þ cells/kg was achieved in 53% (Po0.0001) and 43% (P ¼ 0.03) of patients, respectively.
Toxicity
Mobilization with the use of Ara-C and G-CSF was associated with a 17% incidence of grade 3 neutropenia and a 36% rate of grade 4 neutropenia (Table 4) . No episode of febrile neutropenia was observed, although 8 patients (12%) experienced grade 2 or 3 infections, mostly affecting upper respiratory tract and requiring oral antibiotics. In the CY þ G-CSF group, the incidence of grade 4 neutropenia was significantly higher (70%, Po0.0001) and its duration longer (median 2 versus 0 in the Ara-C cohort, Po0.0001). One patient had febrile neutropenia (P ¼ 0.39), whereas six patients (14%) developed grade 2 or 3 infections (P ¼ 0.37).
Thirty-eight (54%) patients experienced grade 3 thrombocytopenia, and a further 22 individuals (31%) had grade 4 thrombocytopenia after Ara-C þ G-CSF mobilization. Altogether, 35% of patients required platelet transfusions. In the CY þ G-CSF group, the incidence of grade 3 and grade 4 thrombocytopenia was significantly lower (16%, Po0.0001 and 14%, P ¼ 0.04, respectively). The need for platelet transfusions was less frequent (25%), however, the difference did not reach statistical significance (P ¼ 0.22). Requirement for packed RBC transfusions was comparable in two study cohorts.
Non-hematologic adverse events were more frequent among patients treated with CY and G-CSF compared with Ara-C þ G-CSF. Altogether, grade 2 or 3 toxicities were observed in 50 and 23% of patients, respectively (P ¼ 0.004). In particular, administration of CY was associated with higher incidence of grade 2 nausea (18 versus 0%, P ¼ 0.0003). However, grade 3 adverse events were generally rare. No patient experienced grade 4 non-hematologic toxicity. Recovery after autoHSCT Altogether, 67 patients (96%) proceeded to autoHSCT directly after Ara-C þ G-CSF mobilization compared with 27 (60%) in the CY group (Po0.0001). In one patient from each group the transplantation procedure was postponed or canceled due to disease progression, despite collection of sufficient number of hematopoietic stem cells.
Conditioning regimen was based on TBR in 48 and 69% of patients in the Ara-C and CY group, respectively, and the number of transplanted CD34 þ cells was 8.2 Â 10 6 /kg (2.2-24.7) versus 3.9 Â 10 6 /kg (1.4-10.5), respectively (Po0.0001). All patients received G-CSF (filgrastim) 300 mg/d starting from day 7 after autoHSCT until engraftment.
Median time to neutrophil recovery 40.5 Â 10 9 /L was significantly shorter among patients mobilized with Ara-C þ G-CSF than with CY þ G-CSF (median 11 days, range 9-13, mean 11.1, s.d. 0.7 versus median 12 days, range 10-21, mean 12, s.d. 2; P ¼ 0.0004) ( Figure 1 ). As well, the time to platelet recovery 420 Â 10 9 /L was shorter in the Ara-C cohort (median 9 days range 0-17, mean 8. 
DISCUSSION
The search for an optimal mobilization regimen was a subject of a series of prospective, randomized clinical trials, recently reviewed stem cell mobilization with Ara-C S Giebel et al by Sheppard et al. 29 So far, however, no definitive conclusions can be made with regard to the choice of optimal mobilization protocol. 30 Personalized approach, taking into account the presence of factors predicting for poor stem cell harvest together with status of the disease as well as economical and regulatory aspects, is postulated. 29 Therefore, G-CSF alone may be optimal for patients with low risk of mobilization failure and planned single autoHSCT. In contrast, chemomobilization may be /L after autoHSCT according to type of mobilization regimen. Only patients who proceeded to autoHSCT were analyzed that is, 67 subjects mobilized with Ara-C with filgrastim (Ara-C þ G-CSF), and 26 patients treated with CY with filgrastim (CY þ G-CSF). /L after autoHSCT according to type of mobilization regimen. Only patients who proceeded to autoHSCT were analyzed that is, 67 subjects mobilized with Ara-C with filgrastim (Ara-C þ G-CSF), and 26 patients treated with CY with filgrastim (CY þ G-CSF). stem cell mobilization with Ara-C S Giebel et al preferred in high-risk setting and if higher a CD34 þ cell yield is required, for example, for double transplantation procedures. Administration of plerixafor may be considered a good alternative to chemotherapy. However, its availability as a first-line approach is limited in many countries. 29 One of the arguments supporting the use of chemomobilization instead of G-CSF alone is the potential effect of in vivo purging, although the clonogenic potential of malignant cells present in the graft and their clinical significance is unclear. 10, 12, 31, 32 Both Ara-C and CY used in our center are part of various multiagent treatment regimens, and both are expected to have activity against MM and lymphomas.
CY was most frequently used for chemomobilization in clinical trials. 29 Among patients with relapsed NHL, CY at a dose of 5 g/m 2 with G-CSF allowed the collection of a median 7.2 Â 10 6 /kg CD34 þ cells compared with 2.5 Â 10 6 /kg when G-CSF was used as a single agent. 11 Only one prospective study addressed the question of the optimal dosage comparing CY 4 g/m 2 with 1.5 g/m 2 in a mixed population of 27 patients with NHL and breast cancer. 33 Higher doses of CY were associated not only with two times higher CD34 þ cell yields, but also with increased toxicity. In contrast to CY, to the best of our knowledge, intermediate-dose Ara-C as a first-line stem cell mobilization has not been widely evaluated so far.
Efficacy of CY at a dose of 4 g/m 2 þ G-CSF in the current analysis (62% success rate) appears inferior compared with other reports (77-94% success rate). [34] [35] [36] [37] It must be noted, however, that a high proportion of our patients had features associated with high risk of mobilization failure. Despite similar unfavorable characteristics, almost all patients could be successfully mobilized with Ara-C þ G-CSF, with CD34 þ yield sufficient for either single or double autoHSCT, as needed. Importantly, in 62 out of the total 70 patients receiving Ara-C, the harvest could be completed with a single leukapheresis. This compares favorably with intermediatedose CY, which in our study was associated with a median of two leukaphereses, whereas in other reports the median ranged from 2-4.
11,34-37 The advantage of Ara-C over CY in terms of the potency for stem cell mobilization is best reflected by the peak number of peripheral blood CD34 þ cells, which was almost four times higher in the Ara-C group.
Safety issues and related pharmaco-economic aspects are important factors influencing the choice of mobilization regimen. In our center most patients stay in hospital during mobilization, which results from logistic rather than medical reasons. Therefore, the need for hospitalization could not be a relevant end point of our analysis. On the other hand, we noted only 2% rate of febrile neutropenia in the CY group and no event in the Ara-C cohort, which compares favorably with up to 70% in reports were CY at a dose of 4 g/m 2 was administered in an outpatient setting. 38, 39 Non-hematologic toxicities were more frequent after CY than Ara-C but generally very few severe adverse events were noted regardless of the choice of the protocol. Interestingly, the profile of hematologic toxicity was remarkably different for the two regimens. Whereas Ara-C was associated with much higher rate of grade 3 and 4 thrombocytopenia, the use of CY resulted in twice the incidence of profound neutropenia. The differences may reflect diverse pattern of myelosuppression for the two drugs. If so, these findings could constitute the platform for further biological investigation to explain the striking advantage of Ara-C over CY in terms of the mobilization efficacy. CD34 is a surrogate marker of hematopoietic stem cells, although some of them are CD34-negative. 40 Therefore, the number of CD34 þ cells in the product may not necessarily correspond to their clonogenic potential. In our study, there was a trend for a higher number of colonies in the Ara-C compared with the CY group, although this comparison is hampered by the limited number of results. Furthermore, cells collected after Ara-C þ G-CSF mobilization allowed significantly faster neutrophil and platelet recovery after autoHSCT, compared with the CY group.
The difference resulted most probably from over two times higher numbers of transplanted CD34 þ cells in the Ara-C group. Altogether, the above findings confirm high quality of the transplant material obtained using Ara-C-based mobilization.
In conclusion, we demonstrated that intermediate-dose Ara-C in combination with G-CSF is a very effective mobilization protocol allowing adequate stem cell harvest with a single leukapheresis in a vast majority of patients with MM and lymphomas, including 'predicted poor mobilizers'. The efficacy of Ara-C þ G-CSF is significantly higher compared with CY at a dose of 4 g/m 2 þ G-CSF, whereas non-hematologic toxicity-lower. Further investigation is warranted to prospectively evaluate the protocol.
